Zonisamide effects on sleep problems and depressive symptoms in Parkinson's disease.
Parkinson’s disease
Zonisamide
depressive symptoms
motor symptoms
sleep disturbances
Journal
Brain and behavior
ISSN: 2162-3279
Titre abrégé: Brain Behav
Pays: United States
ID NLM: 101570837
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
revised:
09
12
2019
received:
06
06
2019
accepted:
20
12
2020
pubmed:
6
1
2021
medline:
1
7
2021
entrez:
5
1
2021
Statut:
ppublish
Résumé
We aimed to evaluate the effect of zonisamide (ZNS) on motor symptoms and nonmotor symptoms such as depressive symptoms and sleep problems in Parkinson's disease (PD) patients with or without tremor. We conducted a 3-month, open-label study to assess the effects of ZNS on motor symptoms, depressive symptoms and sleep problems. Twenty levodopa-treated PD patients with motor fluctuation completed the study. Patients received 25-50 mg/day of ZNS and were assessed for the Japanese version of the Movement Disorder Society Revision of the Unified PD Rating Scale (MDS-UPDRS) parts I, III, and IV, PD Sleep Scale (PDSS)-2, Beck depression inventory-2 (BDI-II), and PD Questionnaire (PDQ-8) at baseline and after 1, 2 and 3 months of treatment. Patients were categorized into the tremor group and nontremor group to assess changes in clinical parameters. At 3 months, the scores on the MDS-UPDRS parts I, III and IV significantly improved and off-time reduced compared to baseline. Additionally, the PDSS-2 total score significantly decreased at 3 months. Although there were no significant differences in changes in UPDRS part I, III, or IV between the groups after ZNS treatment, the tremor group had significant improvements in PDSS-2 at 3 months and BDI-II at 1, 2 and 3 months compared with the nontremor group. We showed the beneficial effects of ZNS on motor symptoms and sleep problems in levodopa-treated PD patients with motor fluctuation. ZNS may be more effective for several nonmotor symptoms in PD patients with tremor compared with those without tremor.
Sections du résumé
BACKGROUND
We aimed to evaluate the effect of zonisamide (ZNS) on motor symptoms and nonmotor symptoms such as depressive symptoms and sleep problems in Parkinson's disease (PD) patients with or without tremor.
METHODS
We conducted a 3-month, open-label study to assess the effects of ZNS on motor symptoms, depressive symptoms and sleep problems. Twenty levodopa-treated PD patients with motor fluctuation completed the study. Patients received 25-50 mg/day of ZNS and were assessed for the Japanese version of the Movement Disorder Society Revision of the Unified PD Rating Scale (MDS-UPDRS) parts I, III, and IV, PD Sleep Scale (PDSS)-2, Beck depression inventory-2 (BDI-II), and PD Questionnaire (PDQ-8) at baseline and after 1, 2 and 3 months of treatment. Patients were categorized into the tremor group and nontremor group to assess changes in clinical parameters.
RESULTS
At 3 months, the scores on the MDS-UPDRS parts I, III and IV significantly improved and off-time reduced compared to baseline. Additionally, the PDSS-2 total score significantly decreased at 3 months. Although there were no significant differences in changes in UPDRS part I, III, or IV between the groups after ZNS treatment, the tremor group had significant improvements in PDSS-2 at 3 months and BDI-II at 1, 2 and 3 months compared with the nontremor group.
CONCLUSION
We showed the beneficial effects of ZNS on motor symptoms and sleep problems in levodopa-treated PD patients with motor fluctuation. ZNS may be more effective for several nonmotor symptoms in PD patients with tremor compared with those without tremor.
Identifiants
pubmed: 33399276
doi: 10.1002/brb3.2026
pmc: PMC7994695
doi:
Substances chimiques
Zonisamide
459384H98V
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e02026Informations de copyright
© 2021 The Authors. Brain and Behavior published by Wiley Periodicals LLC.
Références
Mov Disord. 2004 Mar;19(3):308-12
pubmed: 15022185
Mov Disord. 2015 Sep;30(10):1343-50
pubmed: 26094993
Mov Disord. 2007 Jan 15;22(2):279-82
pubmed: 17149715
Int J Clin Pract. 2007 Jun;61(6):1050-3
pubmed: 17504366
J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181-4
pubmed: 1564476
Brain Behav. 2021 Mar;11(3):e02026
pubmed: 33399276
J Neurol. 2010 Oct;257(10):1682-5
pubmed: 20509031
J Clin Psychopharmacol. 2006 Aug;26(4):385-8
pubmed: 16855456
Parkinsonism Relat Disord. 2012 Aug;18(7):906-8
pubmed: 22546334
J Neurol Sci. 2012 Jul 15;318(1-2):76-81
pubmed: 22534309
Acta Neurol Scand Suppl. 2012;(194):19-28
pubmed: 23106522
Mov Disord. 2007 Oct 31;22(14):2137-8
pubmed: 17853481
Mov Disord Clin Pract. 2014 Sep 1;1(3):200-212
pubmed: 25328906
Neurology. 2007 Jan 2;68(1):45-50
pubmed: 17200492
Mov Disord. 2010 Nov 15;25(15):2649-53
pubmed: 21069833
Neuropharmacology. 2009 Sep;57(3):322-31
pubmed: 19482038
Epilepsy Res. 1992 Jun;12(1):21-7
pubmed: 1326433
Br J Pharmacol. 1998 Jul;124(6):1277-85
pubmed: 9720801
Epilepsy Res. 1999 Apr;34(2-3):187-97
pubmed: 10210034